{
    "2018-12-19": [
        [
            {
                "time": "2023-10-10",
                "original_text": "Strongbridge completes $181.7M sale of hormone drug to Novo Nordisk",
                "features": {
                    "keywords": [
                        "Strongbridge",
                        "sale",
                        "hormone drug",
                        "Novo Nordisk"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-10",
                "original_text": "Here is What Hedge Funds Think About Novo Nordisk A/S (NVO)",
                "features": {
                    "keywords": [
                        "Hedge Funds",
                        "Novo Nordisk",
                        "opinion"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "financial services",
                        "investing"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}